This is the third time the company is trying to get Illuvien approved, and they didn't do any new studies after the last CRL, despite the FDA requesting them.
Think, folks. What are the chances it gets approved this time? Minimal. This is more than likely someone in the know dumping. Not a bash, but if it looks like a duck and walks like a duck, it probably is.
Illuvien and the 3 year lens which distributes the medication over time HAS ALREADY been approved and used in Europe for chronic and diabetic macular edema which renders people blind, and for which there is no existing treatment other than illuvien or annual injections into the eye sclera. If the FDA doesn't choose to help blind people who have no better alternative then why does the FDA exist. Would they prefer Americans go to Europe and shell out 30 K versus get the treatment here?????
It would appear that the speculation of a bear raid triggering stops is the best explanation so far. You would think a leak would be out by now or be showing on the chart with the price down at the lows or still dropping. We shall see.
or it's a calculated play to buy cheap shares....psdv isn't going down the tubes when it has a very
important delivery method for people who are going blind from a variety of medical conditions including diabetic and chronic macular edema and macular degeneration, as well as uveitis